Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma

• Main Authors: Hongchun Liu, Chao Xiong, Junwen Liu, Ting Sun, Zhenzhen Ren, Yuqing Li, Jie Geng, Xuebing Li
• Format: Article
• Language: English
• Published: Elsevier 2020-05-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Aspirin; Multiple myeloma; Blimp1; ATF4; CHOP
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332220301967

B lymphocyte-induced maturation protein-1 (Blimp1) is a key regulator that promotes the terminal differentiation of mature B lymphocytes into plasma cells, and is essential for the survival of Multiple myeloma (MM)cells. However, the expression of Blimp1 in MM and its effect on the signaling pathway remain unknown. Studies have found that during long-term endoplasmic reticulum (ER) stress, activated ATF4 may also stimulate the CCAAT-enhancer-binding protein homologous protein (CHOP) gene, triggering the unfolded protein response (UPR) terminal apoptotic pathway in plasma cells. Moreover Aspirin can induce MM cell apoptosis through mitochondria and death receptor pathway. Therefore, we aim to explore whether Aspirin could induce AFT4/CHOP apoptosis pathway in MM by inhibiting Blimp1 expression, thereby promoting MM cell apoptosis and exerting anti-tumor effects.